Neximmune Inc

NASDAQ NEXI

Download Data

Neximmune Inc Pre-Tax Margin for the quarter ending March 31, 2024: -220.56%

Neximmune Inc Pre-Tax Margin is -220.56% for the quarter ending March 31, 2024. Pre-tax margin represents the proportion of a company's earnings before taxes (EBT) to its revenue. It is calculated by dividing the EBT by the revenue. This ratio indicates the profitability of the company's operations before the impact of taxes. A higher pre-tax margin suggests that the company generates a larger proportion of revenue as pre-tax profit, indicating stronger operational performance and efficiency.
NASDAQ: NEXI

Neximmune Inc

CEO Ms. Kristi Jones R.Ph.
IPO Date Feb. 12, 2021
Location United States
Headquarters 9119 Gaither Road, Gaithersburg, MD, United States, 20877
Employees 6
Sector Healthcare
Industry Biotechnology
Description

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

Similar companies

IMMX

Immix Biopharma Inc

NA

NA

XBIO

Xenetic Biosciences Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email